Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
FDA nominee says he will follow REMS data and review mifepristone policy if confirmed
Summary
Dr. Marty Makary told senators he will follow the Food and Drug Administration's independent scientific review process and examine ongoing REMS data for mifepristone; several senators pressed for explicit commitments to maintain access and to avoid political interference.
Dr. Marty Makary told the Senate HELP Committee that, if confirmed as FDA commissioner, he would follow the agency’s independent scientific review process and examine the ongoing data collected under the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone.
"I have no preconceived plans to make changes to the mifepristone policy," Dr. Makary said, adding that he would "follow the law and the regulation of the REMS to look at ongoing data." He told senators he would meet with…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
